Showing 3,141 - 3,160 results of 10,415 for search '"XU"', query time: 0.08s Refine Results
  1. 3141
  2. 3142

    Idiopathic Retroperitoneal Fibrosis-Related Hydronephrosis: Evaluation of Comprehensive Management and Prediction of Inflammatory Markers for Stent-Free Outcomes by Huang Z, Liu Y, Xiao Y, Hu H, Xu T

    Published 2025-01-01
    “…Zixiong Huang,1– 3 Yanying Liu,4,5 Yunshu Xiao,5 Hao Hu,1,2 Tao Xu1,2 1Department of Urology, Peking University People’s Hospital, Beijing, 100044, People’s Republic of China; 2Applied Lithotripsy Institute, Peking University, Beijing, 100044, People’s Republic of China; 3Department of Urology, Michigan Medicine, Ann Arbor, MI, 48109, USA; 4Department of Rheumatology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People’s Republic of China; 5Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, 100044, People’s Republic of ChinaCorrespondence: Hao Hu; Tao Xu, Department of Urology, Peking University People’s Hospital, 11 Xizhimen South Street, Beijing, 100044, People’s Republic of China, Email huhao@bjmu.edu.cn; xutao@pkuph.edu.cnObjective: This study investigated the efficacy of comprehensive management and predictable inflammatory markers for idiopathic retroperitoneal fibrosis (iRPF)-related hydronephrosis outcomes.Methods: Patients with iRPF-related hydronephrosis underwent surgical (ureteral stent and/or nephrostomy tube placement) and medical (corticosteroid-based multiple immunosuppressants) management were classified according to stent-indwelling outcomes. …”
    Get full text
    Article
  3. 3143
  4. 3144
  5. 3145
  6. 3146

    Clinical Features and Prognosis of Double-Positive Anti-MDA5 and Anti-CCP Antibodies in Dermatomyositis: A Retrospective Study by Xu X, Zhu L, Li S, Wang G, Ge Y

    Published 2025-02-01
    “…Xiayu Xu,1 Longyang Zhu,2 Sizhao Li,3 Guochun Wang,3 Yongpeng Ge3 1Department of Rheumatology and Immunology, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province, People’s Republic of China; 2Peking University, China-Japan Friendship School of Clinical Medicine, Beijing, People’s Republic of China; 3Department of Rheumatology, The Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, People’s Republic of ChinaCorrespondence: Yongpeng Ge, Department of Rheumatology, The Key Laboratory of Myositis, China-Japan Friendship Hospital, Beijing, 100029, People’s Republic of China, Email gyp2016@163.comObjective: To investigate the clinical features and prognosis of anti-melanoma differentiation-related gene 5 (MDA5) antibody and anti-cyclic citrullinated peptide (CCP) antibody double-positive dermatomyositis (DM) (MDA5+/CCP+ DM).Methods: A retrospective analysis of 264 consecutive cases of MDA5+ DM hospitalized from March 2018 to March 2022, and patients with anti-CCP antibodies were screened out. …”
    Get full text
    Article
  7. 3147
  8. 3148
  9. 3149
  10. 3150
  11. 3151
  12. 3152
  13. 3153
  14. 3154
  15. 3155
  16. 3156
  17. 3157
  18. 3158
  19. 3159
  20. 3160